Navigation Links
Trubion Pharmaceuticals Announces Extension of Research Period Under Its Wyeth Collaboration
Date:6/22/2009

atent or application and, generally, 10 years after the first commercial sale of any product licensed under the agreement. Wyeth may terminate the agreement without cause at any time upon 90 days' written notice.

Trubion retains the right to develop and commercialize, on its own or with others, product candidates directed to all targets not included within the agreement, including CD37.

About Trubion

Trubion is a biopharmaceutical company that is creating a pipeline of novel protein therapeutic product candidates to treat autoimmune and inflammatory diseases and cancer. The Company's mission is to develop a variety of first-in-class and best-in-class product candidates, customized for optimal safety, efficacy and convenience that it believes may offer improved patient experiences. Trubion's current product candidates are novel single-chain protein, or SMIP(TM), therapeutics, and are designed using its custom drug assembly technology. Trubion's product pipeline includes CD20-directed SMIP therapeutics such as TRU-015 and SBI-087 for autoimmune and inflammatory diseases, developed under the Company's Wyeth collaboration. Trubion's product pipeline also includes Trubion's proprietary product candidate, TRU-016, a novel CD37-targeted therapy for the treatment of B-cell malignancies that is currently in Phase 1 / 2 clinical evaluation. In addition to Trubion's current clinical stage product pipeline, the Company is also developing additional product candidates that build on its product development experience. More information is available in the investors section of Trubion's website: http://investors.trubion.com/index.cfm.

Forward-Looking Statements

Certain statements in this release may constitute "forward-looking statements" within the meaning of Sec
'/>"/>

SOURCE Trubion Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Trubion Announces Acceptance of Three Presentations on Its TRU-016 Product Candidate at the 2009 ASCO Annual Meeting
2. Trubion Announces Dates for First-Quarter 2009 Earnings Conference Call
3. Trubion Presents Preclinical Data on Its SCORPION(TM) Multispecific Therapeutics at the 2009 American Association of Cancer Research Annual Meeting
4. Trubion Pharmaceuticals, Inc. Announces Initiation of Phase 1 Study of SBI-087 for the Treatment of Systemic Lupus Erythematosus (SLE)
5. Trubion Pharmaceuticals Inc. Announces Work-Force Reductions and Restructuring
6. Trubion Announces Presentations at Upcoming Investor Conferences
7. Trubion Pharmaceuticals Inc. Reports Third Quarter and Nine Months 2008 Results
8. Trubion Announces Presentations at Upcoming Investor Conferences
9. Trubion Reports Re-treatment Results Following Phase 1/2a and Phase 2b Studies Evaluating TRU-015 for Rheumatoid Arthritis
10. Trubion Pharmaceuticals Wins Patent Opposition - Genentech / Biogen Idec European Patent Revoked
11. Trubion Pharmaceuticals to Present at Fall 2008 Morgan Stanley Global Healthcare Unplugged Conference in New York
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2014)... 2014  Xencor, Inc. (NASDAQ: XNCR ... antibodies for the treatment of autoimmune diseases, asthma ... appointment of Debra Zack , M.D., Ph.D., ... Lloyd Rowland , senior vice president, chief ... "Debra,s expertise in biologics clinical development and medical ...
(Date:9/2/2014)... Winston-Salem, NC and Rocky Mount, NC (PRWEB) September 02, ... (PMG) announced today the establishment of its 11th clinical ... 1, PMG Research has assumed ownership and operation of ... in Rocky Mount, NC, further expanding PMG’s presence in ... to an additional 130,000 patients. For the patients in ...
(Date:9/1/2014)... 1, 2014 Reportlinker.com announces that a ... catalogue: India Solid Waste Management Vehicles ... http://www.reportlinker.com/p02350445/India-Solid-Waste-Management-Vehicles-Market-Forecast-and-Opportunities-2019.html In ... governing bodies responsible for complete handling and regulation ... average, around 135,000 MT solid waste is generated ...
(Date:8/31/2014)... Available spectra is similar for all L-series products ... a wide range of plants. The spectra is ... and pending wide spectrum technology. The single chip ... in contrast to growth spectra made from monochromatic ... large variety of differently sized and shaped growing ...
Breaking Biology Technology:Xencor Appoints Debra Zack, M.D., Ph.D., Vice President, Clinical Development and Lloyd Rowland, Senior Vice President, Chief Compliance Officer and General Counsel 2Xencor Appoints Debra Zack, M.D., Ph.D., Vice President, Clinical Development and Lloyd Rowland, Senior Vice President, Chief Compliance Officer and General Counsel 3PMG Research Announces the Formation of its Eleventh Site 2PMG Research Announces the Formation of its Eleventh Site 3India Solid Waste Management Vehicles Market Forecast and Opportunities, 2019 2India Solid Waste Management Vehicles Market Forecast and Opportunities, 2019 3India Solid Waste Management Vehicles Market Forecast and Opportunities, 2019 4India Solid Waste Management Vehicles Market Forecast and Opportunities, 2019 5India Solid Waste Management Vehicles Market Forecast and Opportunities, 2019 6India Solid Waste Management Vehicles Market Forecast and Opportunities, 2019 7India Solid Waste Management Vehicles Market Forecast and Opportunities, 2019 8
... 3 Ikaria Holdings, Inc., a fully,integrated critical ... CEO, David Shaw, will present at the 26th ... at 3:00 p.m., PST. The,conference will be held ... in San,Francisco., About Ikaria Holdings, Inc., ...
... than 500,000 Total Prescriptions Have Been Dispensed for ... ... 3 Shire plc (LSE: SHP,Nasdaq: SHPGY, TSX: SHQ), the ... from the U.S. Food and Drug,Administration (FDA) for three additional ...
... Jan. 3 Neogen Corporation,(Nasdaq: NEOG ) announced ... FY 2008, which ended Nov. 30, increased 34% from ... split, net income in the,quarter rose to $0.22 per ... net income of $3,254,000 set another quarterly,record for the ...
Cached Biology Technology:FDA Approves Additional Dosage Strengths of Shire's ADHD Treatment VYVANSE(TM) (lisdexamfetamine dimesylate) Which May Help Physicians Tailor Treatment for Individual Patients 2FDA Approves Additional Dosage Strengths of Shire's ADHD Treatment VYVANSE(TM) (lisdexamfetamine dimesylate) Which May Help Physicians Tailor Treatment for Individual Patients 3FDA Approves Additional Dosage Strengths of Shire's ADHD Treatment VYVANSE(TM) (lisdexamfetamine dimesylate) Which May Help Physicians Tailor Treatment for Individual Patients 4FDA Approves Additional Dosage Strengths of Shire's ADHD Treatment VYVANSE(TM) (lisdexamfetamine dimesylate) Which May Help Physicians Tailor Treatment for Individual Patients 5Neogen Reports 34% Increase in Net Income, 23% Increase in Revenues 2Neogen Reports 34% Increase in Net Income, 23% Increase in Revenues 3Neogen Reports 34% Increase in Net Income, 23% Increase in Revenues 4Neogen Reports 34% Increase in Net Income, 23% Increase in Revenues 5
(Date:9/1/2014)... decisions of the Nomenclature Section of the XVIII International ... 2011. This meeting is held every six years and ... rules for naming algae, fungi and plants get together ... the organisms they study. This is the primary product ... algae, fungi, and plants, which was published in 2012. ...
(Date:8/31/2014)... fast and accurate tool to diagnose tuberculosis in ... developed test (TAM-TB assay) is the first reliable ... The test features excellent specificity, a similar sensitivity ... a blood test. The promising findings are a ... children, particularly in tuberculosis-endemic regions. , The study ...
(Date:8/31/2014)... of the greatest challenges in modern medicine is developing ... with minimal toxicity and side-effects to the patient. Such ... the drug molecule. Ideally, the drug should have a ... so that it binds it with high specificity. Publishing ... a synthetic amino acid that can impact the 3D ...
Breaking Biology News(10 mins):Week-long meeting on naming algae, fungi, and plants recorded for posterity 2New tuberculosis blood test in children is reliable and highly specific 2A new synthetic amino acid for an emerging class of drugs 2A new synthetic amino acid for an emerging class of drugs 3
... WORCESTER, Mass. Orthopedic surgeons are often hamstrung ... bone injuries resulting from trauma, aging or cancer. Conventional ... or brittle ceramics, and cannot readily conform to the ... in addition, they often require metallic fixation devices that ...
... Swiss needle cast epidemic in Douglas-fir forests of the coastal ... over at least the past 100 years, and is probably ... and a warmer climate, new research concludes. Scientists in ... found that this disease, which is affecting hundreds of thousands ...
... the University of Alabama at Birmingham (UAB) have been ... Scholarship and Excellence in Education Foundation. Atbin Doroodchi, ... Biology and Mathematics. He has a 3.95 grade-point average ... Honors Program. Doroodchi is an undergraduate researcher in the ...
Cached Biology News:Smart orthopedic implants and self-fitting tissue scaffolding created by UMMS researchers 2Forest epidemic is unprecedented phenomenon, still getting worse 2Forest epidemic is unprecedented phenomenon, still getting worse 3Forest epidemic is unprecedented phenomenon, still getting worse 43 UAB students awarded prestigious Goldwater scholarships 2
... Clone/PAD: ZMD.358. Immunogen: Synthetic ... region of human mouse and ... with human and mouse LRP5 ... (positive controls: mouse LRP5-pSEC-tag-transfected 293T ...
MarrowMAX Bone Marrow Medium...
... recognizes murine IRF7 protein, and ... related IRF proteins. Reactivity of ... protein was confirmed by western ... cells transfected with IRF7. Reactivity ...
Rabbit anti-phospho-EGFr (Tyr992) - Concentrate...
Biology Products: